Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127321 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01127321 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 44 participants.
The verdict
NCT01127321, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI-570 0.03 MG
- BIOLOGICAL MEDI-570 0.1 MG
- BIOLOGICAL MEDI-570 0.3 MG
- BIOLOGICAL MEDI-570 1 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127321
The ClinicalTrials.gov registry entry for NCT01127321 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01127321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127321 about?
NCT01127321 is a clinical study titled "A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus". The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
What is the current status of trial NCT01127321?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01127321?
The interventions under investigation include: Placebo (OTHER), MEDI-570 0.03 MG (BIOLOGICAL), MEDI-570 0.1 MG (BIOLOGICAL), MEDI-570 0.3 MG (BIOLOGICAL), MEDI-570 1 MG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01127321?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.